Stay updated on M7824 and Eribulin in Metastatic TNBC Clinical Trial
Sign up to get notified when there's something new on the M7824 and Eribulin in Metastatic TNBC Clinical Trial page.

Latest updates to the M7824 and Eribulin in Metastatic TNBC Clinical Trial page
- Check4 days agoChange DetectedThe study record now indicates termination of the trial due to sponsor decision, with updated completion and enrollment dates.SummaryDifference0.4% 
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference3% 
- Check33 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1% 
- Check47 days agoChange DetectedThe page now shows Revision: v3.0.2 (replacing v3.0.1), and the 'Back to Top' link has been removed.SummaryDifference0.2% 
- Check54 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2% 
- Check61 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as the introduction of new drug names such as Eribulin Mesylate and bintrafusp alfa protein. However, several related topics and previous drug names have been removed.SummaryDifference2% 
Stay in the know with updates to M7824 and Eribulin in Metastatic TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the M7824 and Eribulin in Metastatic TNBC Clinical Trial page.